The stock of Vericel Corp (NASDAQ:VCEL) is a huge mover today! The stock increased 4.26% or $0.1 on November 23, hitting $2.45. About 219,632 shares traded hands. Vericel Corp (NASDAQ:VCEL) has declined 22.22% since April 22, 2016 and is downtrending. It has underperformed by 27.63% the S&P500.
The move comes after 5 months positive chart setup for the $60.35M company. It was reported on Nov, 24 by Barchart.com. We have $2.67 PT which if reached, will make NASDAQ:VCEL worth $5.43M more.
Analysts await Vericel Corp (NASDAQ:VCEL) to report earnings on March, 13.
Vericel Corp (NASDAQ:VCEL) Ratings Coverage
Out of 2 analysts covering Vericel (NASDAQ:VCEL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Vericel has been the topic of 3 analyst reports since March 11, 2016 according to StockzIntelligence Inc. As per Friday, March 11, the company rating was upgraded by Needham. Needham maintained the stock with “Buy” rating in Wednesday, November 9 report. The firm has “Neutral” rating by Bank of America given on Tuesday, April 5.
According to Zacks Investment Research, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.”
More news for Vericel Corp (NASDAQ:VCEL) were recently published by: Marketwatch.com, which released: “Vericel Corp. NASDAQ: VCEL” on November 28, 2014. Quotes.Wsj.com‘s article titled: “News Vericel Corp.VCEL” and published on November 27, 2014 is yet another important article.
VCEL Company Profile
Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., incorporated on March 24, 1989, is a commercial-stage biopharmaceutical firm dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Firm operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns approximately 30% of total body surface area (TBSA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.